HMA in combination with venetoclax and magrolimab in the treatment of AML

Novel combinations being explored in AML using an HMA-venetoclax backboneПодробнее

Venetoclax and magrolimab for treatment of AML and MDSПодробнее

Phase Ib/II study of magrolimab in combination with azacitidine and venetoclax in patients with AMLПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Magrolimab in combination with azacitidine in untreated AMLПодробнее

Magrolimab + azacitidine in TP53-mutant AMLПодробнее

Case 4: Treating AML With HMA/VenetoclaxПодробнее

Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AMLПодробнее

Predictors of poor response to azacitidine, venetoclax, and magrolimab in TP53-mutated AMLПодробнее

CPX-351 vs. HMA plus venetoclax in the treatment of patients with AMLПодробнее

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy comboПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AMLПодробнее

Magrolimab plus azacitidine in treatment-naïve AMLПодробнее

AML: options after venetoclax-based regimen failureПодробнее

Magrolimab with azacitidine in patients with AMLПодробнее

Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AMLПодробнее

Magrolimab + azacitidine in MDS and AMLПодробнее

Exploring the Data for AML Treated With Magrolimab and AzacitidineПодробнее